Findings

What do systematic reviews say?

21 questions · 21 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 42.9%GRADE not reported 0 · 0%Very low 10 · 47.6%Low 2 · 9.5%Moderate 0 · 0%High 0 · 0%

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Serum deposition Cmax · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 126 participants
Low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Adverse events · adults and children with cystic fibrosis

It is very uncertain whether summary of findings ‐ nebulisers for delivering tobramycin:… changes adverse events compared with VMT (very low certainty).

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.78 [0.37, 1.64]
2 studies · 60 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Participant satisfaction or preference · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Treatment time nebulisation time (min) · children aged 6 ‐ 18 with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Quality of life · children aged 6 ‐ 18 with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Serum deposition Cmax · children aged 6 ‐ 18 with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Adverse events · children aged 6 ‐ 18 with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

FEV1 (% predicted): mean change from baseline · children aged 6 ‐ 18 with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Time to next exacerbation · children aged 6 ‐ 18 with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Participant satisfaction or preference · children aged 6 ‐ 18 with cystic fibrosis

It is very uncertain whether summary of findings ‐ nebulisers for delivering tobramycin:… changes participant satisfaction or preference Satisfaction scale compared with VMT and AAD (very low certainty).

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
MD 2.7 [1.35, 4.05]
1 study · 22 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Treatment time (min) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Serum deposition Cmax · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

FEV1 · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Participant satisfaction or preference · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Treatment time (min) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 103 participants
Low